ClinicalTrials.gg
RecruitingNCT06945120Updated Mar 13, 2026

ACT Lung Health Intervention: Phase Two

An interventional study of ACT Lung Health Intervention in Smoking Cessation, Smoking Behaviors and Smoking, Tobacco, sponsored by Dana-Farber Cancer Institute. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 921 studies in Smoking Cessation with a site in United States — 98 open to participants now, 127 under way, 7 of them phase 3. Smoking Cessation · United States.

Planned enrollment
648th of 873
50 · median 148
Started
2025
with 27 others
No phase
513 of 921
69 open now
Primary completion
2026-11
later than 24 of 126 live
Registered
870th of 921
by date

Among the 921 studies in Smoking Cessation with a site in United States, this one is the 648th largest by planned enrollment of the 873 interventional ones that give a count, is one of 28 that started in 2025, is one of 513 with no phase, reaches primary completion later than 24 of the 126 other live ones, and was the 870th registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

98 of the 921 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 921 studies in Smoking Cessation with a site in United States, or all of them as a file.
02

Study summary

This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.

Read the detailed description

This two-arm stratified randomized clinical trial is to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.

Participants will be randomized into one of two groups: Group A: ACT Lung Health Intervention versus Group B: Standard Care. Randomization means a participant is placed into a study group by chance.

The research study procedures include screening for eligibility, questionnaires, and saliva tests.

It is expected participation in this study will last about 6 months.

About 50 participants are expected to take part in this research study.

The National Cancer Institute is providing funding for this trial.

03

Conditions studied

  • Smoking Cessation
  • Smoking Behaviors
  • Smoking, Tobacco
  • Smoking, Cigarette
  • Smoking (Tobacco) Addiction

Keywords

  • Smoking Cessation
  • Lung Cancer Screening
  • Smoking (Tobacco) Addiction
  • Smoking, Cigarette
  • Smoking, Tobacco
  • Smoking Behaviors
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Self-identify as either Chinese or Korean
  • Speak either Korean, Mandarin, or English
  • Are 18 years of age or older
  • Are current smokers (i.e., have smoked at least 100 traditional cigarettes ever and have smoked at least one traditional cigarette within the prior 30 days)
  • Will live in the United States for the next 12 months

Exclusion criteria

Exclusion Criteria:

  • Hospitalization due to a serious mental illness (e.g., psychotic disorders) during the prior 6 months.
  • We will not include any of the following special populations:

    • Adults unable to consent.
    • Adults younger than 50 or older than 80 years
    • Individuals who are not yet adults (infants, children, teenagers)
    • Pregnant women
    • Prisoners
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Group A: ACT Lung Health Intervention

    Participants will be randomized 1:1 in blocks, stratified by ethnicity and readiness to quit smoking and will complete: * Baseline assessment * Eight telephone or video counseling sessions over 8 weeks * Nicotine replacement therapy (NRT) patches, gums and lozenges will be provided * Written educational materials on lung cancer screening will be provided * Assessments at 1, 3, and 6 months * 3 month saliva test * 6 month saliva test

    Behavioral: ACT Lung Health Intervention

  • No intervention
    Group B: Standard Care

    Participants will be randomized 1:1 in blocks, stratified by ethnicity and readiness to quit smoking and will complete: * Baseline assessment * Six telephone or video counseling sessions over 8 weeks * Nicotine replacement therapy (NRT) patches, gums and lozenges will be provided * Written educational materials on lung cancer screening will be provided * Assessments at 1, 3, and 6 months * 3 month saliva test * 6 month saliva test

Interventions

  • BehavioralACT Lung Health Intervention

    An Asian culture-tailored lung health intervention, which includes individual counseling sessions, family coaching, provision of nicotine replacement therapy (NRT) in the form of patches, lozenges, or chewing gum, and educational materials about low-dose computed tomography (LDCT) for lung cancer screening. The eight weekly, counseling sessions with study staff will be conducted via phone call or the Zoom web-conferencing platform.

    Also known as: Asian Culturally Tailored Lung Health (ACT) Intervention

06

What researchers measure

Primary outcomes

  1. Biochemically Verified 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group A)

    The proportion of participants who have not smoked cigarettes (not even a puff) in the past 7 days at the 6-month follow-up, verified biochemically using salivary cotinine testing. Participants reporting abstinence and not using nicotine replacement therapy (NRT) will perform a salivary cotinine test observed via video call. Cotinine levels ≤3 ng/mL will confirm abstinence.

    Time frame: 6 months post-baseline assessment

  2. Biochemically Verified 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group B)

    The proportion of participants who have not smoked cigarettes (not even a puff) in the past 7 days at the 6-month follow-up, verified biochemically using salivary cotinine testing. Participants reporting abstinence and not using nicotine replacement therapy (NRT) will perform a salivary cotinine test observed via video call. Cotinine levels ≤3 ng/mL will confirm abstinence.

    Time frame: 6 months post-baseline assessment

Secondary outcomes

  1. Change in Number of Cigarettes Smoked per Day from Baseline to 6 Months (Group A)

    The mean change in the number of cigarettes smoked by participants per day from baseline to 6 months post-baseline.

    Time frame: Baseline and 6 months post-baseline assessment

  2. Change in Number of Cigarettes Smoked per Day from Baseline to 6 Months (Group B)

    The mean change in the number of cigarettes smoked by participants per day from baseline to 6 months post-baseline.

    Time frame: Baseline and 6 months post-baseline assessment

  3. Self-Reported 7-Day Point Prevalence Smoking Abstinence at 3 Months (Group A)

    The proportion of participants who self-report not smoking cigarettes (not even a puff) in the past 7 days at the 3-month follow-up.

    Time frame: 3 months post-baseline assessment

  4. Self-Reported 7-Day Point Prevalence Smoking Abstinence at 3 Months (Group B)

    The proportion of participants who self-report not smoking cigarettes (not even a puff) in the past 7 days at the 3-month follow-up.

    Time frame: 3 months post-baseline assessment

  5. Self-Reported 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group A)

    The proportion of participants who self-report not smoking cigarettes (not even a puff) in the past 7 days at the 6-month follow-up.

    Time frame: 6 months post-baseline assessment

  6. Self-Reported 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group B)

    The proportion of participants who self-report not smoking cigarettes (not even a puff) in the past 7 days at the 6-month follow-up.

    Time frame: 6 months post-baseline assessment

  7. Completion of Lung Cancer Screening with Low-Dose Computed Tomography (LDCT) at 6 Months (Group A)

    The proportion of participants eligible for lung cancer screening who have completed lung cancer screening using LDCT within 6 months after baseline assessment. Completion will be verified by self-report and/or by obtaining a copy of the LDCT results from participants.

    Time frame: Within 6 months post-baseline assessment

  8. Completion of Lung Cancer Screening with Low-Dose Computed Tomography (LDCT) at 6 Months (Arm B)

    The proportion of participants eligible for lung cancer screening who have completed lung cancer screening using LDCT within 6 months after baseline assessment. Completion will be verified by self-report and/or by obtaining a copy of the LDCT results from participants.

    Time frame: Within 6 months post-baseline assessment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 12 months is below that.

Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2025
First posted
Apr 25, 2025
StartActual
Nov 4, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06945120
Collaborators
National Cancer Institute (NCI), University of Massachusetts, Boston
Responsible party
Mary E. Cooley, Phd (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Apr 25, 2025
Start date
Nov 4, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 13, 2026

Study contacts

Mary Cooley, PhD
Contact
mary_cooley@dfci.harvard.edu
617-632-5096
Barbara Halpenny, MA, MSW
Contact
barbara_halpenny@dfci.harvard.edu
617-582-7124
Mary Cooley, PhD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion